Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States?

Current Hypertension Reports

Volumn 8, Issue 3, 2006, Pages 219-225

  Hawkins, Ralph G ^a  

^a Manitoba Clinic   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; IRBESARTAN; LISINOPRIL; METOLAZONE; NIFEDIPINE; NITRENDIPINE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

CLINICAL TRIAL; DRUG MECHANISM; DRUG USE; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; GLOMERULOSCLEROSIS; HEMODIALYSIS; HUMAN; HYPERTENSION; HYPOTHESIS; IN VITRO STUDY; KIDNEY FAILURE; KIDNEY FIBROSIS; META ANALYSIS; NEPHROTOXICITY; NONHUMAN; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; UNITED STATES;

ANIMALS; DIURETICS; HYPERTENSION; INCIDENCE; KIDNEY FAILURE, CHRONIC; POPULATION SURVEILLANCE; UNITED STATES;

EID: 33744953787     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-006-0054-3     Document Type: Review

References (43)

1. Goldman L, Cook EF: The decline in ischemic heart disease mortality rates. An analysis of the comparative effects of medical interventions and changes in lifestyle. Ann Intern Med 1984, 101:825-836.
2. Gallup G Jr, Cotugno HE: Preferences and practices of Americans and their physicians in antihypertensive therapy. Am J Med 1986, 81:20-24.
3. Hawkins RG, Houston MC: Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States? A hypothesis. Am J Hypertens 2005, 18:744-749.
4. Russell A, Remington P, D'Alessio D, Brazy P: Increasing incidence of end-stage renal disease in Wisconsin: An unintended consequence of increased survival? WMJ 2001, 100:35-38.
5. Brenner BM: Brenner and Rector's The Kidney, edn 6. Philadelphia: WB Saunders; 2000:135.
6. Komatsu K, Numabe A, Ono Y, Frohlich ED: Hydrochlorothiazide increases efferent glomerular arteriolar resistance in spontaneously hypertensive rats. J Cardiovasc Pharm Ther 1996, 1:57-64.
7. Westphal S, Rading A, Luley C, Dierkes J: Antihypertensive treatment and homocysteine concentrations. Metabolism 2003, 52:261-263.
8. Lottermoser K, Hertfelder HJ, Vetter H, Dusing R: Fibrinolytic function in diuretic-induced volume depletion. Am J Hypertens 2000, 13:359-363.
9. Mikhail N, Fukuda N, Tremblay J, Hamet P: Platelets, growth factors, and vascular smooth-muscle cells in hypertension and diabetes. J Cardiovasc Pharmacol 1993, 22(Suppl 6):S64-S74.
10. Kasiske BL, Ma JZ, Kalil RSN, Louis TA: Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995, 122:133-141.
11. Ohman KP, Karlberg BE, Nilsson OR, Wettre S: Captopril, aldosterone and urinary kallikrein in primary hypertension. Clin Exp Hypertens A 1983, 5:523-529.
12. Benigni A, Zoja C, Noris M, et al.: Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. Am J Kidney Dis 1999, 33:746-753.
13. Roman MJ, Alderman MH, Pickering TG, et al.: Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy. Am J Hypertens 1998, 11:387-396.
14. Klahr S, Morrissey J: Progression of chronic renal disease. Am J Kidney Dis 2003, 41:S3-S7.
15. Mann B, Hartner A, Jensen BL, et al.: Furosemide stimulates macula densa cyclooxygenase-2 expression in rats. Kidney Int 2001, 59:62-68.
16. Wang JL, Cheng HF, Shappell S, Harris RC: A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progression of renal injury in rats. Kidney Int 2000, 57:2334-2342.
17. Ono Y, Ono H, Frohlich ED: Hydrochlorothiazide exacerbates nitric oxide-blockade nephrosclerosis with glomerular hypertension in spontaneously hypertensive rats. J Hypertens 1996, 14:823-828.
18. Francischetti A, Ono H, Frohlich ED: Renoprotective effects of felodipine and/or enalapril in spontaneously hypertensive rats with and without L-NAME. Hypertension 1998, 31:795-801.
19. Nakamura Y, Ono H, Zhou X, Frohlich ED: Angiotensin type 1 receptor antagonism and ACE inhibition produce similar renoprotection in N(omega)-nitro-L-arginine methyl ester/ spontaneously hypertensive rats. Hypertension 2001, 37:1262-1267.
20. Madkour H, Gadallah M, Riveline B, et al.: Comparison between the effects of indapamide and hydrochlorothiazide on creatinine clearance in patients with impaired renal function and hypertension. Am J Nephrol 1995, 15:251-255.
21. Rajapakse JC, DeCarli C, McLaughlin A, et al.: Cerebral magnetic resonance image segmentation using data fusion. Nenroradiology 1996, 20:206-218.
22. Mitiche A, Aggarwal JK: Multiple sensor integration/fusion through image processing: a review. Opt Eng 1986, 25:380-386.
23. Luo RC, Kay MG: Multisensor integration and fusion in intelligent systems. IEEE Trans Systems Man Cybernet 1989, 19:909-931.
24. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997, 157:2413-2446.
25. Psaty BM, Lumley T, Furberg CD, et al.: Health outcomes associated with various antihypertensive therapies used as first-line agents. JAMA 2003, 289:2534-2544.
26. Medical Research Council Working Party: MRC trial of treatment of mild hypertension: principal results. Br Med J (Clin Res Ed) 1985, 291:97-104.
27. Fletcher A, Amery A, Birkenhager W, et al.: Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. J Hypertens 1991, 9:225-230.
28. Coope J, Warrender TS: Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986, 293:1145-1151.
29. Ekborn T, Dahlof B, Hansson L, et al.: Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOP Hypertension study. J Hypertens 1992, 10:1525-1530.
30. Coresh J, Wei G L, McQuillan G, et al.: Prevalence of high blood pressure and elevated serum creatinine level in the United States. Arch Intern Med 2001, 161:1207-1216.
31. Voyaki SM, Staessen JA, Thijs L, et al.: Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. J Hypertens 2001, 19:511-519.
32. Savage PJ, Pressel SL, Curb JD, et al.: Influence of long-term low-dose diuretic-based antihypertensive therapy on glucose, lipid, uric acid and potassium levels in older men and women with isolated systolic hypertension. The Systolic Hypertension in the Elderly Program. Arch Intern Med 1999, 158:741-751.
33. Brown MJ, Palmer CR, Castaigne A, et al.: Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000, 356:366-372.
34. The ALLHAT Study Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vs. diuretic. JAMA 2002, 288:2981-2997.
35. Dahlof B, Sever PS, Poulter NR, et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentered randomised controlled trial. For the ASCOT Investigators. Lancet 2005, 366:907-913.
36. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group Preserving Renal Function in Adults with Hypertension and Diabetes: A Consensus Approach. Am J Kidney Dis 2000, 36:646-661.
37. Rahman M, Pressel S, Davis B, et al.: Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic. For the ALLHAT Collaborative Research Group. Arch Intern Med 2005, 165:936-946.
38. Psaty BM, Lumley T, Furberg CD: Research Letter. Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies. JAMA 2004, 292:43-44.
39. Casas JP, Chua W, Loukogeorgakis S, et al.: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005, 10:2026-2026.
40. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. For the Collaborative Study Group. N Engl J Med 2001, 345:851-860.
41. Medscape article accessed on Jan 8, 2005 at: http://www.medscape.com/viewarticle/456055
42. Moser M, MacAulay AI: Chlorothiazide as an adjunct in the treatment of essential hypertension. Am J Cardiol 1959, 2:214-219.
43. Basile J: Analysis of recent papers in hypertension. Does diuretic use lead to an increased risk of subsequent end-stage renal disease? J Clin Hypertens 2005, 7:491-492.